Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026

Author: Totus Medicines

Posted Date: